MAP2K7 and breast cancer: Thus, WT-GSK-3 can alter the sensitivity to MEK inhibitors in PDAC cells with mutant KRAS. In contrast, we did not observe a significant difference in sensitivity to MEK inhibitors in MCF-7 breast cancer cells which have WT-KRAS upon treatment with MEK inhibitors by themselves [37].